Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2007 2
2008 2
2009 6
2010 4
2011 3
2016 1
2017 1
2018 1
2019 1
2020 1
2021 7
2022 7
Text availability
Article attribute
Article type
Publication date

Search Results

32 results
Results by year
Filters applied: . Clear all
Page 1
Effect of Therapeutic Drug Monitoring vs Standard Therapy During Infliximab Induction on Disease Remission in Patients With Chronic Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial.
Syversen SW, Goll GL, Jørgensen KK, Sandanger Ø, Sexton J, Olsen IC, Gehin JE, Warren DJ, Brun MK, Klaasen RA, Karlsen LN, Noraberg G, Zettel C, Ljoså MKA, Haugen AJ, Njålla RJ, Bruun TJ, Seeberg KA, Michelsen B, Strand EK, Skorpe S, Blomgren IM, Bragnes YH, Dotterud CK, Thune T, Ystrøm CM, Torp R, Mielnik P, Mørk C, Kvien TK, Jahnsen J, Bolstad N, Haavardsholm EA. Syversen SW, et al. JAMA. 2021 May 4;325(17):1744-1754. doi: 10.1001/jama.2021.4172. JAMA. 2021. PMID: 33944876 Free PMC article. Clinical Trial.
Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial.
Syversen SW, Jørgensen KK, Goll GL, Brun MK, Sandanger Ø, Bjørlykke KH, Sexton J, Olsen IC, Gehin JE, Warren DJ, Klaasen RA, Noraberg G, Bruun TJ, Dotterud CK, Ljoså MKA, Haugen AJ, Njålla RJ, Zettel C, Ystrøm CM, Bragnes YH, Skorpe S, Thune T, Seeberg KA, Michelsen B, Blomgren IM, Strand EK, Mielnik P, Torp R, Mørk C, Kvien TK, Jahnsen J, Bolstad N, Haavardsholm EA. Syversen SW, et al. JAMA. 2021 Dec 21;326(23):2375-2384. doi: 10.1001/jama.2021.21316. JAMA. 2021. PMID: 34932077 Free PMC article. Clinical Trial.
Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study.
Jyssum I, Kared H, Tran TT, Tveter AT, Provan SA, Sexton J, Jørgensen KK, Jahnsen J, Kro GB, Warren DJ, Vaage EB, Kvien TK, Nissen-Meyer LH, Anderson AM, Grødeland G, Haavardsholm EA, Vaage JT, Mjaaland S, Syversen SW, Lund-Johansen F, Munthe LA, Goll GL. Jyssum I, et al. Among authors: syversen sw. Lancet Rheumatol. 2022 Mar;4(3):e177-e187. doi: 10.1016/S2665-9913(21)00394-5. Epub 2021 Dec 23. Lancet Rheumatol. 2022. PMID: 34977602 Free PMC article.
Serum etanercept concentrations in relation to disease activity and treatment response assessed by ultrasound, biomarkers and clinical disease activity scores: results from a prospective observational study of patients with rheumatoid arthritis.
Gehin JE, Syversen SW, Warren DJ, Goll GL, Sexton J, Bolstad N, Hammer HB. Gehin JE, et al. Among authors: syversen sw. RMD Open. 2021 Dec;7(3):e001985. doi: 10.1136/rmdopen-2021-001985. RMD Open. 2021. PMID: 34911811 Free PMC article.
Serum golimumab concentration and anti-drug antibodies are associated with treatment response and drug survival in patients with inflammatory joint diseases: data from the NOR-DMARD study.
Gehin JE, Warren DJ, Syversen SW, Lie E, Sexton J, Loli L, Wierød A, Bjøro T, Kvien TK, Bolstad N, Goll GL. Gehin JE, et al. Among authors: syversen sw. Scand J Rheumatol. 2021 Nov;50(6):445-454. doi: 10.1080/03009742.2021.1875040. Epub 2021 Mar 2. Scand J Rheumatol. 2021. PMID: 33650469
Testing of the preliminary OMERACT validation criteria for a biomarker to be regarded as reflecting structural damage endpoints in rheumatoid arthritis clinical trials: the example of C-reactive protein.
Keeling SO, Landewe R, van der Heijde D, Bathon J, Boers M, Garnero P, Geusens P, El-Gabalawy H, Inman RD, Kraus VB, Kvien TK, Mease PJ, Ostergaard M, Ritchlin C, Syversen SW, Maksymowych WP. Keeling SO, et al. Among authors: syversen sw. J Rheumatol. 2007 Mar;34(3):623-33. J Rheumatol. 2007. PMID: 17343310 Review.
Reappraisal of OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage endpoints in rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis: the OMERACT 9 v2 criteria.
Maksymowych WP, Landewé R, Tak PP, Ritchlin CJ, Ostergaard M, Mease PJ, El-Gabalawy H, Garnero P, Gladman DD, Fitzgerald O, Aletaha D, Bykerk VP, Bathon JM, Syversen SW, Boers M, Geusens P, Inman RD, Kraus VB, Kvien TK, Taylor WJ, Wells GA, van der Heijde D. Maksymowych WP, et al. Among authors: syversen sw. J Rheumatol. 2009 Aug;36(8):1785-91. doi: 10.3899/jrheum.090346. J Rheumatol. 2009. PMID: 19671813
Proposal for levels of evidence schema for validation of a soluble biomarker reflecting damage endpoints in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, and recommendations for study design.
Maksymowych WP, Fitzgerald O, Wells GA, Gladman DD, Landewé R, Ostergaard M, Taylor WJ, Christensen R, Tak PP, Boers M, Syversen SW, Bathon JM, Ritchlin CJ, Mease PJ, Bykerk VP, Garnero P, Geusens P, El-Gabalawy H, Aletaha D, Inman RD, Kraus VB, Kvien TK, van der Heijde D. Maksymowych WP, et al. Among authors: syversen sw. J Rheumatol. 2009 Aug;36(8):1792-9. doi: 10.3899/jrheum090347. J Rheumatol. 2009. PMID: 19671814
32 results